← All trials
NCT06994442
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 20, 2025
- Primary completion
- Jul 31, 2029
- Completion date
- Aug 31, 2029
- First posted
- May 29, 2025
- Last posted
- Nov 14, 2025
- Enrollment
- 644
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cornell UniversityLead sponsor
- Cornell UniversityOfficial
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.